AR and prostate carcinoma: Furthermore, AR expression declines after cell passaging [62] and the most commonly used prostate cancer cell line for AR studies, LNCaP [2–4], expresses a mutated form of the gene (T877A) that can modify its ligand-binding site and signalling [63].